Zogenix to Release Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 10

Rhea-AI Summary

Zogenix, a biopharmaceutical company focused on rare disease therapies, will report its financial results for the third quarter of 2020 on November 10, 2020, at 4:30 PM ET. The company’s lead product, FINTEPLA, is approved for treating seizures in Dravet syndrome and is under development for other conditions. Zogenix is committed to transforming patient lives with innovative therapies. The conference call will offer insights into the company’s financial performance and ongoing projects.

Positive

• Zogenix's FINTEPLA has received FDA approval for Dravet syndrome, indicating strong regulatory progress.
• The company is advancing late-stage development for additional rare disease therapies, enhancing growth potential.

Negative

• None.

EMERYVILLE, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the three and nine months ended September 30, 2020 and host a corporate update conference call and webcast after the market close on Tuesday, November 10, 2020, at 4:30 PM Eastern Time.

Conference Call Details
Tuesday, November 10, at 4:30 PM Eastern Time / 1:30 PM Pacific Time
Toll Free:	877-407-9716
International:	201-493-6779
Conference ID:	13711927
Webcast:	http://public.viavid.com/index.php?id=141969

About Zogenix
Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company’s first rare disease therapy, FINTEPLA® (fenfluramine) oral solution has been approved by the U.S. FDA and received a positive CHMP opinion in Europe for the treatment of seizures associated with Dravet syndrome, a rare, severe childhood onset epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, a different rare childhood-onset epilepsy and another for MT1621, an investigational novel substrate enhancement therapy for the treatment of TK2 deficiency, a rare genetic disorder. MT1621 is being developed through Modis Therapeutics, a Zogenix company.

Zogenix 
Melinda Baker 
Senior Director, Corporate Communications 
+1 (510) 788-8732 | corpcomms@zogenix.com 

Investors 
Brian Ritchie 
Managing Director, LifeSci Advisors LLC 
+1 (212) 915-2578 | britchie@lifesciadvisors.com 

Media 
In Europe: Kerry Lloyd-Jones, Account Director, Porter Novelli
+44 (0) 7949 794 290 | kerry.lloyd-jones@porternovelli.co.uk
In the US: Stefanie Tuck, Vice President, Porter Novelli
+1 (978) 390-1394 | stefanie.tuck@porternovelli.com

 

FAQ

When will Zogenix report its financial results for the third quarter of 2020?

Zogenix will report its financial results on November 10, 2020, at 4:30 PM ET.

What is Zogenix's lead product and what condition does it treat?

Zogenix's lead product is FINTEPLA, which is approved for treating seizures associated with Dravet syndrome.

What additional therapies is Zogenix developing?

Zogenix is developing FINTEPLA for Lennox-Gastaut syndrome and MT1621 for TK2 deficiency.